Benefits of glatiramer acetate on disability in relapsing-remitting multiple sclerosis: An analysis by area under disability/time curves

Journal of the Neurological Sciences

Volumn 181, Issue 1-2, 2000, Pages 33-37

  Liu, C ^a   Blumhardt, L D ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Area under the curve; Disability; Glatiramer acetate; Multiple sclerosis; Outcome measures

Indexed keywords

GLATIRAMER;

AREA UNDER THE CURVE; ARTICLE; CALCULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DRUG EFFICACY; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MORBIDITY; MULTIPLE SCLEROSIS; OUTCOMES RESEARCH; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; TECHNIQUE;

DISABILITY EVALUATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTICENTER STUDIES; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATIENT ACCEPTANCE OF HEALTH CARE; PEPTIDES; RECOVERY OF FUNCTION; STATISTICAL DISTRIBUTIONS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0034542016     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(00)00401-9     Document Type: Article

References (25)

1. Summary measure statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis
2. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial
3. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
4. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability
5. The natural history of multiple sclerosis: A geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials
6. Clinical outcome measures and rating scales in multiple sclerosis trials
7. Analysis of serial measurements in medical research
8. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up
9. The natural history of multiple sclerosis: A geographically based study. 2. Predictive value of the early clinical course
10. Scales for rating impairment in multiple sclerosis: A critique
11. Outcomes assessment in multiple sclerosis clinical trials, a critical analysis
12. Clinical scales for multiple sclerosis
13. The psychometric properties of clinical rating scales used in multiple sclerosis
14. Kurtzke scales revisited: The application of psychometric methods to clinical intuition
15. Intramuscular interferon β-1a for disease progression in relapsing multiple sclerosis
16. Interferons in the treatment of multiple sclerosis. Do they prevent the progression of the disease?
17. Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: Effects of heterogeneity of disease course in placebo cohorts
18. Assessing relapses in treatment trials of relapsing and remitting multiple sclerosis: Can we do better?
19. A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache
20. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome
21. Inpatient rehabilitation in multiple sclerosis. Do the benefits carry over into the community?
22. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
23. Randomised, double blind, placebo controlled study of interferon β-1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curves
24. Copolymer 1: A most reasonable alternative therapy for early relapsing-remitting multiple sclerosis with mild disability
25. Reply to correspondence by Simonian N.A., McAllister A., Hull J., Summary measure statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis